LYBALVI

Peak

olanzapine and samidorphan l-malate

NDAORALTABLET
Approved
May 2021
Lifecycle
Peak
Competitive Pressure
0/100

Mechanism of Action

unclear; however, its efficacy in the treatment of schizophrenia or bipolar I disorder could be mediated through a combination of dopamine and serotonin type 2 (5HT 2 ) antagonism. The mechanism of action of samidorphan could be mediated through opioid receptor antagonism.

Pharmacologic Class:

Atypical Antipsychotic

Indications (1)

Loss of Exclusivity

LOE Date
Nov 12, 2041
191 months away
Patent Expiry
Nov 12, 2041
Exclusivity Expiry
May 28, 2026

Patent Records (5)

Patent #ExpiryTypeUse Code
12194035
Aug 23, 2031
U-3141
10716785
Aug 23, 2031
U-3136
11185541
Aug 23, 2031
U-3140
11241425
Aug 23, 2031
U-3137
11351166
Aug 23, 2031
U-3141